| 1.52 0.09 (6.29%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.22 | 1-year : | 2.69 |
| Resists | First : | 1.9 | Second : | 2.3 |
| Pivot price | 1.48  |
|||
| Supports | First : | 1.25 | Second : | 1.04 |
| MAs | MA(5) : | 1.38 |
MA(20) : | 1.66 |
| MA(100) : | 1.56 |
MA(250) : | 1.59 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.8 |
D(3) : | 9.3 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 6.15 | Low : | 1.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BIVI ] has closed below upper band by 42.3%. Bollinger Bands are 44.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 26 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.55 - 1.56 | 1.56 - 1.56 |
| Low: | 1.37 - 1.37 | 1.37 - 1.38 |
| Close: | 1.53 - 1.54 | 1.54 - 1.55 |
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Fri, 31 Jul 2026
[S-1/A] BIOVIE INC. Amends IPO Registration Statement - Stock Titan
Thu, 30 Jul 2026
BioVie Inc (BIVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Thu, 30 Jul 2026
BIVI|BioVie Inc|Price:1.540|Chg%:+0.110 - TradingKey
Mon, 27 Jul 2026
BIVI|BioVie Inc|Price:1.440|Chg%:+0.180 - TradingKey
Sun, 26 Jul 2026
BioVie Inc (BIVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fri, 24 Jul 2026
BioVie Inc. Revenue Breakdown – NASDAQ:BIVI - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 13.9 (%) |
| Shares Short | 655 (K) |
| Shares Short P.Month | 300 (K) |
| EPS | -3.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -61.1 % |
| Return on Equity (ttm) | -106.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.41 |
| PEG Ratio | 0 |
| Price to Book value | 0.74 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|